ReviewSignal transduction and targeted therapy2026
Diabetes and its complications: molecular mechanisms, prevention and treatment.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of traditional Chinese medicine decoctions in breast cancer treatment: a network meta-analysis.Frontiers in oncology · 2026Pooled it
- Artificial intelligence-guided nanozyme engineering for chronic wound healing: from rational design to precision therapeutics.Bioactive materials · 2027Review
- CRISPR Technologies in Type 2 Diabetes: From Mechanistic Insights to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- Polyunsaturated Fatty Acids and Diabetic Kidney Disease: What have We Learned so Far?Current nutrition reports · 2026Review
- Effect of Lactiplantibacillus plantarum SCS6 on pancreatic oxidative damage in mice with type 2 diabetes based on gut-pancreas axis.Antonie van Leeuwenhoek · 2026Article
- Antimicrobial Peptides for Diabetic Foot Ulcers and Infections: Current Evidence and Translational Perspectives.International journal of molecular sciences · 2026Review
- From xanthine oxidase inhibition to inflammasome regulation: exploring the potential role of allopurinol in TXNIP-NLRP3 signaling and pyroptosis in diabetes.Inflammopharmacology · 2026Review
- Effects of MCC950 on lipid profiles, glycemic control, and sympathetic dysfunction in a streptozotocin-induced type 1 diabetic rat model.Croatian medical journal · 2026Article
- Consensus In Silico Pharmacodynamic Screening of Twelve Fabaceae Isoflavones Targeting Glycation, Oxidative Stress, Antidiabetic Activity, and NF-κB-Related Inflammation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Magnesium and Diabetes: A Review of Recent Studies on the Efficacy of Supplementation with Mg in Humans Suffering from This Chronic Metabolic Disease.International journal of molecular sciences · 2026Review
- Ultrasound-Assisted Ionic Liquid Extraction, Macroporous Resin Purification, and Hypoglycemic Effects of Total Flavonoids fromMolecules (Basel, Switzerland) · 2026Article
- Guanxinning Tablet Ameliorates Erectile Dysfunction in Diabetes Mellitus Rats with Involvement of PI3K/Akt/FOXO1 Signaling Pathway Modulation.Biomedicines · 2026Article
- Galectin-3, transforming growth factor beta 1, and brain natriuretic peptide in cardiac remodeling under hyperlipidemic and hyperglycemic stress.Molecular and cellular biochemistry · 2026Article
- Combined sleep behaviors, mediating biomarkers, and incident vascular complications among individuals with type 2 diabetes: A prospective study in UK Biobank.Journal of diabetes investigation · 2026Article
- From In Silico to Clinic: Harnessing Noncoding RNAs for Diabetes Research and Therapy, a Step toward ncRNA Precision.ACS pharmacology & translational science · 2026Review
- Impact of Imatinib Therapy on Immunometabolism to Promote β-Cell Survival in Diabetes.Journal of diabetes · 2026Article
- Allopurinol Beyond Gout: Targeting Oxidative Stress and Metabolic Inflammation in Diabetes and Its Complications.International journal of rheumatic diseases · 2026Article
- Mechanotransduction Failure and Molecular Rescue in Gastric Cancer: Kinetotherapy Across the IL-6/STAT3-Myostatin/ACVR2B-Akt/mTOR Axis.Medical sciences (Basel, Switzerland) · 2026Review
- HIF inhibition: Current strategies and clinical challenges.Redox biology · 2026Review
- Joint association of TyG-ABSI composite index and inflammatory score with diabetes in middle-aged and older Chinese adults: a prospective cohort study from CHARLS (2011-2020).BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic complications represent a formidable clinical challenge characterized by hyperglycemia-induced multiorgan dysfunction and dysregulated intercellular signaling networks. Advances in spatial multiomics and single-cell transcriptomic techniques, along with insights into aberrant signaling via myokines, cytokines, hormones, the gut microbiota, and exosomes, have revealed the molecular heterogeneity and dynamic inter-organ crosstalk underlying diabetes. Digital diabetes prevention programs have demonstrated effectiveness in high-risk populations through the use of remote tools to support lifestyle changes, reduce hemoglobin A1c, and delay the onset of type 2 diabetes. The therapeutic landscape for diabetic complications has been reshaped by agents with proven cardiorenal benefits, including sodium‒glucose cotransporter 2 inhibitors, glucagon‒like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists, with combination therapies offering potential additive or synergistic effects. However, their optimal application requires careful benefit-risk assessment across diverse patient populations. Novel therapeutic strategies involving mesenchymal stem cells and their derived exosomes, gut microbiota modulation, bioactive compounds from traditional Chinese medicine, and AI-assisted disease management systems offer promising approaches to correct molecular dysfunctions. This review summarizes recent advances in the mechanisms, prevention, and treatment of diabetic complications, alongside a critical examination of current bottlenecks in translational applications. The remaining challenges include establishing long-term safe regenerative therapies and effectively integrating AI into clinical workflows. Although AI shows promise, issues such as limited data diversity and low model interpretability hinder its generalizability and clinical trust. Addressing these challenges will be essential for transitioning toward a proactive, personalized, and patient-centered model of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.